Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Invesco S&P 500 Low Volatility ETF — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B), while Invesco S&P 500 Low Volatility ETF trades at $73.8 (market cap $7.06B). The key difference: Kymera Therapeutics Inc. Common Stock is the larger of the two by market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Invesco S&P 500 Low Volatility ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Invesco S&P 500 Low Volatility ETF for 124 Days on average.
| KYMR | SPLV | |
|---|---|---|
Market Cap | $8.87B | $7.06B |
Volume | 779,107 | 1,461,921 |
Sector | Health | — |
52-Week High | $127.31 | $77.97 |
52-Week Low | $55.80 | $70.30 |
Typical Hold Time | 0 Days | 124 Days |
Enterprise Value | $8.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SPLV trades at $72.98, up 0.26% with a bullish technical signal from moving averages, though oscillators show neutral momentum. The ETF's sector allocation to utilities and real estate has lagged the broader market, returning 5% versus the S&P 500's 17% year-to-date. Recent dividend payments of $0.14 provide income stability amid market volatility.
Outlook remains cautious as growth-adjusted valuations appear stretched at 19.5x P/E. Risks include sector concentration and macroeconomic pressures, but SPLV offers defensive exposure during market uncertainty. The neutral analyst stance reflects balanced near-term prospects between stability benefits and performance headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
